Update regarding call options issued by the main owners to senior executives

Report this content

On August 27, 2021, SyntheticMR AB (publ) ("SyntheticMR") announced that the company's principal shareholders had agreed with senior executives (CEO and Head of US region) on purchase a total of 300,000 call options. According to the terms at the program's introduction, the time for invoking the excercising of shares with the support of call options was determined between June 2023 and June 2025. Each call option included the right to aquire one new share in SyntheticMR. The excercise price per share was set at an amount of SEK 50. In light of the development of the share price, the parties deem the original incentive has lost its intended effect. The parties have therefore agreed to adjust the option agreement's original model. Instead, the number of call options will be reduced to 217,200 and the period of use for the call options will be moved forward to the period June 2024 to June 2026. Each call option also further includes the right to aquire a new share in SyntheticMR. Other conditions are left unchanged.

This disclosure contains information that SyntheticMR AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 15-02-2023 18:02 CET.

For additional information, please contact Ulrik Harrysson, CEO, SyntheticMR AB, +46 70 529 29 87 ulrik.harrysson@syntheticmr.com.

SyntheticMR AB develops and markets innovative software solutions for Magnetic Resonance Imaging (MRI). SyntheticMR AB has developed SyMRI®, delivering multiple, adjustable contrast images and quantitative data from a single 5-minute scan. The SyMRI product is available in different packages. SyMRI NEURO delivers multiple contrast images, tissue segmentations and quantitative data on the brain. SyMRI MSK provides multiple contrast images and quantitative data for knee and spine anatomies. SyMRI NEURO is CE-marked and FDA 510(k) cleared and SyMRI MSK is CE-marked. SyMRI is a registered trademark in Europe and the USA. SyntheticMR is listed on the Spotlight Stock Market Exchange in Stockholm, Sweden. For more information, visit www.syntheticmr.com.


Documents & Links